Model-Informed Precision Dosing
 | This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (September 2024) |
Model-Informed Precision Dosing (MIPD for short) is the use of computer models and computer simulations, first developed in the 1960s, with the simultaneous integration of therapeutic drug monitoring, to create a drug dosing scheme for humans. MIPD may offer a better benefit-harm ratio compared to conventional dosing for certain drugs. It is applied by a physician using specialized software as part of their treatment. MIPD is particularly suitable for special patient groups, such as frail elderly patients, pediatric patients, patients with kidney or liver dysfunction and seriously ill patients. Due to numerous limitations, MIPD is currently rarely used in clinical practice.[1][2]
References
[edit]- ^ Adam S. Darwich, Thomas M. Polasek, Jeffrey K. Aronson, Kayode Ogungbenro, Daniel F.B. Wright, Brahim Achour, Jean-Luc Reny, Youssef Daali, Birgit Eiermann, Jack Cook, Lawrence Lesko, Andrew J. McLachlan, Amin Rostami-Hodjegan: Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy. In: Annual Review of Pharmacology and Toxicology. 61, 2021, S. 225, doi:10.1146/annurev-pharmtox-033020-113257.
- ^ W. Kantasiripitak, R. Van Daele, M. Gijsen, M. Ferrante, I. Spriet, E. Dreesen: Software Tools for Model-Informed Precision Dosing: How Well Do They Satisfy the Needs? In: Frontiers in pharmacology. Band 11, 2020, S. 620, doi:10.3389/fphar.2020.00620, PMID 32457619, PMC 7224248.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |